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EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer
A fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the 
anaplastic lymphoma kinase (ALK) has been identified in non-small cell lung cancers 
(NSCLCs). Although a few studies have evaluated EML4-ALK fusion genes in Korean 
NSCLCs, the prevalence of different EML4-ALK fusion variants has yet to be clearly 
assessed. Herein, we have examined the profiles of EML4-ALK fusion gene variants in 
Korean patients of NSCLCs. EML4-ALK fusion genes have been detected in 10 (6.0%) of 
167 patients of NSCLCs and in 9 (7.4%) of 121 patients of adenocarcinoma. Of the 10 
patients with fusion genes identified, 8 (80%) were E13;A20 (variant 1) and 2 (20%) were 
E6;A20, with an additional 33-bp sequence derived from intron 6 of EML4 (variant 3b). 
These results indicate that the profiles of EML4-ALK fusion gene variants in Korean patients 
of NSCLC may differ from those in other ethnic populations. Herein, we describe for the 
first time the profiles of EML4-ALK fusion variants of Korean patients with NSCLCs.
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BRIEF COMMUNICATION
Oncology & Hematology
Non-small cell lung cancer (NSCLC) accounts for approximate-
ly 80%-85% of all cases of lung cancer, and is the leading cause 
of cancer deaths worldwide including Korea, with only 15% of 
patients surviving for more than 5 yr (1-3). Although cytotoxic 
chemotherapy remains the mainstay treatment for the majority 
of patients with advanced NSCLC, molecular-targeted therapy 
played an increasingly important role, particularly in genetical-
ly defined subsets of patients (4). Therefore, the identification 
of patients that harbor genetic alterations of the key oncogene 
for NSCLC is extremely important for selecting those most like-
ly to derive benefit from a specific molecular targeted agent (5). 
  The echinoderm microtubule-associated protein-like 4 (EML4)-
anaplastic lymphoma kinase (ALK) fusion oncogene resulting 
from the chromosome inversion inv(2) (p21; p23) represents a 
novel molecular target in NSCLC. Since its first report by Soda 
et al. (6), the EML4-ALK fusion gene has been indentified in 3%-
7% of NSCLCs (7). Additionally, ALK kinase inhibitors have been 
developed and have been shown to be highly effective in NSCLCs 
harboring EML4-ALK fusion gene (8-10). Therefore, it is clearly 
imperative to identify NSCLC patients with EML4-ALK fusion 
gene (11).
  Thus far, multiple EML4-ALK variants have been identified in 
NSCLCs (7, 12). All involve the intracellular tyrosine kinase do-
main of ALK beginning at the portion encoded for by exon 20. 
However, EML4 is variably truncated (occurring at exons 2, 6, 
13, 14, 15, 18, and 20) and gives rise to diverse variants of EML4-
ALK. Among the variants known thus far, it has been reported 
that E13;A20 (the nomenclature refers to the exon in EML4 [E] 
fused to the exon of ALK [A], variant 1) and E6a/b;A20 (variant 
3a/b) are the most common variants, accounting for 33% and 
29%, respectively, of all the EML4-ALK variants identified in 
NSCLCs (7, 12). Although a few studies have evaluated EML4-
ALK fusion genes in Korean NSCLCs (13, 14), the prevalence of 
different EML4-ALK fusion variants has not been particularly 
well studied. Considering the differences in genetic and envi-
ronmental factors related to lung cancer, it is possible that the 
profile of EML4-ALK fusion variants in the context of Korean 
lung cancer may differ from those of other countries. To answer 
this question, we evaluated EML4-ALK fusion variants using 
reverse-transcriptase-polymerase chain reaction (RT-PCR) in 
Korean NSCLCs.
  Tumor and corresponding non-malignant lung tissue speci-Jin G, et al.  •  EML4-ALK Fusion Gene in Non-Small Cell Lung Cancer
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mens were provided by the National Biobank of Korea - Kyung-
pook National University Hospital, Daegu, Korea, which is sup-
ported by the Ministry of Health, Welfare, and Family Affairs. 
All materials derived from the National Biobank were obtained 
in accordance with institutional review board-approved proto-
col, Kyungpook National University Medical Center (Approval 
No., KNUHBIO_10_1016). 
  This study included 167 NSCLC patients who underwent cu-
rative resection at the Kyungpook National University Hospital, 
in Daegu, Korea between January 2001 and December 2009. 
Patients who underwent chemotherapy or radiotherapy prior 
to surgery were excluded in order to avoid effects on RNA. All 
patients included in this study were ethnic Koreans. This study 
included 46 patients with squamous cell carcinoma (SCC) and 
121 patients with adenocarcinoma (AC). The study cohort com-
prised 85 males and 82 females. The patient population com-
prised 94 never-smokers and 73 smokers. Of the 121 patients 
with AC, 93 were never-smokers. All of the tumor and macro-
scopically-normal lung tissue samples were obtained at the time 
of surgery, then rapidly frozen in liquid nitrogen and stored at 
-80
oC. Only tumors with greater than 80% of the tumor compo-
nent were sent for analysis. 
  Total RNA was extracted from fresh frozen tissues using the 
RNeasy Mini kit (Qiagen Valencia, CA, USA), and the RNA ex-
tract was incubated with RNase-free DNase I (Qiagen) to remove 
contaminating DNA. Reverse transcription of total RNA was 
carried out using a Qiagen kit to generate complementary DNA 
(cDNA). In order to identify all possible EML4-ALK fusion cDNA, 
we conducted RT-PCR assays using two sense primers (5´-TCA- 
CTGTGCTAAAGGCGGCTTTGG-3´, on exon 2 of EML4, and 
5´-CCACACCTGGGAAAGGACCTAAAG-3´, on exon 13 of EML4) 
and a single antisense primer (5´-CAGGGCTTCCATGAGGAA- 
ATCCAG-3´, on exon 22 of ALK). PCR reactions were performed 
in a total volume of 20 μL containing 50 ng of cDNA, 0.2 mM of 
each primer, 0.2 mM dNTPs, 1 unit of Taq polymerase (Takara, 
Shuzo Co., Otus, Shiga, Japan), and 1 ×  reaction buffer (10 mM 
Tris-HCl [pH8.3], 50 mM KCl, and 1.5 mM MgCl2). The PCR cy-
cle conditions consisted of an initial denaturation step at 95
oC 
for 5 min, followed by 35 cycles of 30 sec at 95
oC; 30 sec at 66
oC; 
30 sec at 72
oC; and a final elongation at 72
oC for 10 min. We used 
the primers 5´-GTCAGTGGTGGACCTGACCT-3´ (forward) and 
5´-TGAGCTTGACAAAGTGGTCT-3´ (reverse) to amplify the 
glycer-aldehyde-3-phospate dehydrogenase (GAPDH) gene as 
an internal control. GAPDH amplification was carried out by 
preincubation for 5 min at 95
oC for initial denaturation, followed 
by 35 cycles of 30 sec at 95
oC; 30 sec at 58
oC; 30 sec at 72
oC; and 
a final elongation at 72
oC for 10min. The PCR products were 
purified using a GENECLEAN Turbo kit (Q-Biogene, Carlsbad, 
CA, USA). Sequencing was performed using an ABI Prism 3100 
Genetic Analyzer (PE Biosystems, Foster City, CA, USA). We 
also analyzed mutations in the EGFR (exons 18-21), ERBB2 (ex-
ons 19-20) and KRAS (exon 2) genes in the tumors harboring 
EML4-ALK fusion genes using PCR and direct sequencing, as 
described in our previous study (15).
  Using RT-PCR, EML4-ALK fusion transcripts were detected 
in 10 (6.0%) of the 167 NSCLCs. When the patients were strati-
fied by median age, the fusion transcripts were significantly more 
Table 1. Relations between EML4-ALK fusion gene and clinicopathologic features
Features    No.
Fusion gene, No. (%)
P value
 Positive  Negative
All subjects 167 10 (6.0) 157 (94.0)
Age (yr)
   ≤ 64 
   > 64
  
93
74
  
  10 (10.8)
  0 (0.0)
  
  83 (89.2)
    74 (100.0)
  
0.002
Gender
   Male
   Female
 
85
82
 
  4 (4.7)
  6 (7.3)
 
  81 (95.3)
  76 (92.7)
 
0.351
Smoking status
   Ever
   Never
 
73
94
 
  3 (4.1)
  7 (7.4)
 
  70 (95.9)
  87 (92.6)
 
0.288
Pack-years of smoking*
   < 30
   ≥ 30
 
23
50
 
  1 (4.3)
  2 (4.0)
 
  22 (95.7)
  48 (96.0)
 
0.685
Histology
   Squamous cell carcinoma
   Adenocarcinoma
 
46
121
 
  1 (2.2)
  9 (7.4)
 
  45 (97.8)
112 (92.6)
 
0.183
Pathologic stage
   Stage I 
   Stage II-IIIA
 
93
74
 
  4 (4.3)
  6 (8.1)
  89 (95.7)
  68 (91.9)
0.241
*In ever-smokers.
Marker
279
346 72
347
517
351
646
694
194
495
Variant 3b
Variant 1
A
B
C
Fig. 1. Detection of EML4-4LK fusion genes by RT-PCR and sequencing. RT-PCR     
results of 10 positive cases with EML4-ALK fusion genes (A). Necleotide sequencing 
of the PCR products of variant 1 (B) and variant 3b (C).Jin G, et al.  •  EML4-ALK Fusion Gene in Non-Small Cell Lung Cancer
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common in younger patients than in older patients (10.8% vs 
89.2%, P = 0.002). The fusion transcripts were more common in 
females, never-smokers, and ACs than in males, smokers, and 
SCCs, respectively, although not statistically significant (Table 1). 
All of 10 patients who harbored the EML4-ALK fusion transcripts 
had no mutations in EGFR, ERBB2, and KRAS genes. Nucleotide 
sequencing of the PCR products for the 10 identified positive 
cases revealed that 8 specimens (80%) harbored variant 1 (E13; 
A20), and 2 specimens (20%) harbored variant 3b (E6;A20 with 
an additional 33-bp sequence derived from intron 6 of EML4) 
(Fig. 1). 
  In this study, the frequency of EML4-ALK fusion genes in our 
series of NSCLCs was 6.0% (7.4% in ACs), which was consistent 
with the frequency of 3%-13% reported in East Asian patients 
with NSCLC (7, 12). Additionally, this was also similar to the fre-
quency reported in a previous Korean study (4.2% of NSCLCs 
and 6.8% in ACs) (13), in which EML4-ALK fusion genes were 
analyzed by fluorescence in situ hybridization (FISH). 
  FISH is a standard method for detection of ALK rearrange-
ment. However, unlike PCR, FISH cannot distinguish between 
different EML4-ALK fusion variants. Therefore, we employed 
RT-PCR assays to evaluate the profile of EML4-ALK fusion gene 
variants in Korean NSCLCs. Notably, the E13;A20 (variant 1) and 
E6a;A20 (variant 3b) account for 80% and 20%, respectively, of 
all the EML4-ALK variants identified in the current study. This 
frequency distribution of EML4-ALK fusion variants differed 
from those reported among other ethnic populations (7). Al-
though all known variants have been demonstrated to possess 
potent oncogenic activity, it is possible that these different fu-
sion variants have functional or therapeutic differences. There-
fore, future studies will be required to clarify whether there are 
any functional or therapeutic differences amongst the different 
fusion variants. 
  One must consider a number of limitations of the present study. 
Because this study included only cases with available RNA, the 
demographic and clinicopathologic characteristics of the study 
population were somewhat different from those of a nationwide 
lung cancer survey (16). In addition, the results of RT-PCR anal-
ysis were not confirmed by FISH. Therefore, there might be false 
positive results (7). 
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